Gilead’s Livdelzi shows promise in PBC clinical trial

Gilead Sciences has reported two-and-a-half-year interim analysis outcomes from a Phase III study of Livdelzi (seladelpar) for treating primary biliary cholangitis (PBC).

The analysis revealed that 81% of individuals treated with Livdelzi achieved a composite biochemical response (CBR), indicating substantial improvements in PBC progression markers.